Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
Autologous stem cell transplant (ASCT) is the standard of care in transplant-eligible multiple myeloma patients and is associated with significant improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS). However, majority of patients eventually relaps...
Saved in:
Main Authors: | Zeina Al-Mansour, Muthalagu Ramanathan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2014/652395 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01) -
The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
by: Eko A. Pangarsa, et al.
Published: (2021-01-01) -
Multiple Myeloma in a Patient with ANKRD26-Related Thrombocytopenia Successfully Treated with Combination Therapy and Autologous Stem Cell Transplant
by: Muhammad Husnain, et al.
Published: (2019-01-01) -
Predictive factors of thrombosis during autologous stem cell transplantation in multiple myeloma: Experience from EHU Oran (Algeria)
by: Mohammed Amine BEKADJA, et al.
Published: (2022-06-01) -
Predictive factors of thrombosis during autologous stem cell transplantation in multiple myeloma: Experience from EHU Oran (Algeria)
by: Mohammed Amine BEKADJA, et al.
Published: (2022-06-01)